Oxetorone: Difference between revisions

	WikiDoc Resources for Oxetorone
Articles
Most recent articles on Oxetorone Most cited articles on Oxetorone Review articles on Oxetorone Articles on Oxetorone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Oxetorone Images of Oxetorone Photos of Oxetorone Podcasts & MP3s on Oxetorone Videos on Oxetorone
Evidence Based Medicine
Cochrane Collaboration on Oxetorone Bandolier on Oxetorone TRIP on Oxetorone
Clinical Trials
Ongoing Trials on Oxetorone at Clinical Trials.gov Trial results on Oxetorone Clinical Trials on Oxetorone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Oxetorone NICE Guidance on Oxetorone NHS PRODIGY Guidance FDA on Oxetorone CDC on Oxetorone
Books
Books on Oxetorone
News
Oxetorone in the news Be alerted to news on Oxetorone News trends on Oxetorone
Commentary
Blogs on Oxetorone
Definitions
Definitions of Oxetorone
Patient Resources / Community
Patient resources on Oxetorone Discussion groups on Oxetorone Patient Handouts on Oxetorone Directions to Hospitals Treating Oxetorone Risk calculators and risk factors for Oxetorone
Healthcare Provider Resources
Symptoms of Oxetorone Causes & Risk Factors for Oxetorone Diagnostic studies for Oxetorone Treatment of Oxetorone
Continuing Medical Education (CME)
CME Programs on Oxetorone
International
Oxetorone en Espanol Oxetorone en Francais
Business
Oxetorone in the Marketplace Patents on Oxetorone
Experimental / Informatics
List of terms related to Oxetorone

Oxetorone
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N02CX06 (WHO) ;
Identifiers
	IUPAC name (3Z)-3-[1]benzofuro[3,2-c][1]benzoxepin-6(12H)-ylidene-N,N-dimethylpropan-1-amine;
CAS Number	26020-55-3 ;
PubChem CID	6436540;
UNII	T3XOS33TIQ;
KEGG	D08312 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C21H21NO2
Molar mass	319.40 g/mol
3D model (JSmol)	Interactive image;
	SMILES CN(C)CCC=C1C2=CC=CC=C2OCC3=C1OC4=CC=CC=C34;
(verify)

VisualWikitext

Latest revision as of 16:52, 20 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Oxetorone (INN), as oxetorone fumarate (USAN) (brand names Nocertone, Oxedix), is a serotonin antagonist, antihistamine, and alpha blocker used as an antimigraine drug.^[1]^[2]^[3]^[4]

Association with hyperprolactinemia has been described.^[5]

References

↑ C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1493–. ISBN 978-0-412-46630-4.
↑ William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
↑ C.J. van Boxtel; B. Santoso; I.R. Edwards (6 August 2008). Drug Benefits and Risks: International Textbook of Clinical Pharmacology - Revised 2nd Edition. IOS Press. pp. 699–. ISBN 978-1-60750-345-3.
↑ Massiou H (2000). "[Prophylactic treatments of migraine]". Rev. Neurol. (Paris) (in French). 156 Suppl 4: 4S79–86. PMID 11139754.
↑ Pradalier A (December 1996). "Hyperprolactinaemia and depression induced by oxetorone". Cephalalgia. 16 (8): 560–1. doi:10.1046/j.1468-2982.1996.1608560.x. PMID 8980859.

Template:Antimigraine preparations

[GanellinTriggle1996-1] C.R. Ganellin; David J. Triggle (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 1493–. ISBN 978-0-412-46630-4.

[Publishing2013-2] William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.

[BoxtelSantoso2008-3] C.J. van Boxtel; B. Santoso; I.R. Edwards (6 August 2008). Drug Benefits and Risks: International Textbook of Clinical Pharmacology - Revised 2nd Edition. IOS Press. pp. 699–. ISBN 978-1-60750-345-3.

[pmid11139754-4] Massiou H (2000). "[Prophylactic treatments of migraine]". Rev. Neurol. (Paris) (in French). 156 Suppl 4: 4S79–86. PMID 11139754.

[pmid8980859-5] Pradalier A (December 1996). "Hyperprolactinaemia and depression induced by oxetorone". Cephalalgia. 16 (8): 560–1. doi:10.1046/j.1468-2982.1996.1608560.x. PMID 8980859.

[1]

[2]

[3]

[4]

[5]

@@ Line 1: / Line 1: @@
-__NOTOC__
+{{Drugbox
+| verifiedrevid = 444750715
+| IUPAC_name = (3''Z'')-3-[1]benzofuro[3,2-''c''][1]benzoxepin-6(12''H'')-ylidene-''N,N''-dimethylpropan-1-amine
+| image = Oxetorone.png
+| width = 180
+| alt = Ball-and-stick model
+| image2 = 360px-Oxetorone-3D-balls.png
+| alt2 = Ball-and-stick model
+<!--Clinical data-->
+| tradename =
+| Drugs.com = {{drugs.com|international|oxetorone}}
+| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
+| pregnancy_US = <!-- A / B            / C / D / X -->
+| pregnancy_category =
+| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
+| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
+| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
+| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
+| legal_status =
+| routes_of_administration =
+<!--Pharmacokinetic data-->
+| bioavailability =
+| protein_bound =
+| metabolism =
+| elimination_half-life =
+| excretion =
+<!--Identifiers-->
+| CAS_number_Ref = {{cascite|correct|??}}
+| CAS_number = 26020-55-3
+| ATC_prefix = N02
+| ATC_suffix = CX06
+| PubChem = 6436540
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+| DrugBank =
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = T3XOS33TIQ
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = D08312
+<!--Chemical data-->
+| chemical_formula =
+| C=21 | H=21 | N=1 | O=2
+| molecular_weight = 319.40 g/mol
+| smiles = CN(C)CCC=C1C2=CC=CC=C2OCC3=C1OC4=CC=CC=C34
+}}
+                     __NOTOC__
+{{SI}}
+{{CMG}}
+==Overview==
+'''Oxetorone''' ([[International Nonproprietary Name|INN]]), as '''oxetorone fumarate''' ([[United States Adopted Name|USAN]]) (brand names '''Nocertone''', '''Oxedix'''), is a [[serotonin antagonist]], [[antihistamine]], and [[alpha blocker]] used as an [[antimigraine drug]].<ref name="GanellinTriggle1996">{{cite book|author1=C.R. Ganellin|author2=David J. Triggle|title=Dictionary of Pharmacological Agents|url=http://books.google.com/books?id=A0THacd46ZsC&pg=PA1493|date=21 November 1996|publisher=CRC Press|isbn=978-0-412-46630-4|pages=1493–}}</ref><ref name="Publishing2013">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia, 3rd Edition|url=http://books.google.com/books?id=_J2ti4EkYpkC&pg=PA2935-IA131|date=22 October 2013|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=2935–}}</ref><ref name="BoxtelSantoso2008">{{cite book|author1=C.J. van Boxtel|author2=B. Santoso|author3=I.R. Edwards|title=Drug Benefits and Risks: International Textbook of Clinical Pharmacology - Revised 2nd Edition|url=http://books.google.com/books?id=idbvAgAAQBAJ&pg=PA699|date=6 August 2008|publisher=IOS Press|isbn=978-1-60750-345-3|pages=699–}}</ref><ref name="pmid11139754">{{cite journal |author=Massiou H |title=[Prophylactic treatments of migraine] |language=French |journal=Rev. Neurol. (Paris) |volume=156 Suppl 4 |issue= |pages=4S79–86 |year=2000 |pmid=11139754 |doi= |url=http://www.masson.fr/masson/79997}}</ref>
+Association with [[hyperprolactinemia]] has been described.<ref name="pmid8980859">{{cite journal |author=Pradalier A |title=Hyperprolactinaemia and depression induced by oxetorone |journal=Cephalalgia |volume=16 |issue=8 |pages=560–1 |date=December 1996 |pmid=8980859 |doi= 10.1046/j.1468-2982.1996.1608560.x|url=http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0333-1024&date=1996&volume=16&issue=8&spage=560}}</ref>
+==References==
+{{Reflist|2}}
+{{Antimigraine preparations}}
+[[Category:Alpha blockers]]
+[[Category:Antimigraine drugs]]
+[[Category:H1 receptor antagonists]]
+[[Category:Heterocyclic compounds (3 rings)]]
+[[Category:Drug]]

Oxetorone: Difference between revisions

Latest revision as of 16:52, 20 August 2015

Overview

References

Navigation menu

Search